- Moleculin Biotech (MBRX, Financial) participated in a Virtual Investor segment to discuss FDA feedback on the Pediatric Study Plan for Annamycin.
- CEO Walter Klemp highlighted the drug's potential for treating children with relapsed/refractory acute myeloid leukemia (R/R AML).
- The segment, focused on Annamycin's development for hard-to-treat tumors and viruses, is available online.
Moleculin Biotech, Inc. (MBRX), a late-stage pharmaceutical company, recently engaged in a Virtual Investor segment titled “What This Means.” In this session, the company elaborated on the favorable feedback received from the FDA regarding the Pediatric Study Plan for Annamycin, a next-generation anthracycline. Annamycin is being developed to address critical medical needs in children suffering from relapsed or refractory acute myeloid leukemia (R/R AML).
Walter Klemp, the Founder, President, CEO, and Chairman of Moleculin, led the discussion. He emphasized the company's advancements in creating therapeutic solutions for challenging tumors and viral infections. Annamycin, in particular, stands out for its design intended to avoid multidrug resistance and eliminate the common cardiotoxicity of existing anthracyclines.
The Virtual Investor segment is now accessible online for those interested in the company's progress and future potential in treating R/R AML among pediatric patients.
